Related Experiment Video
Updated: Jun 28, 2026
Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis
Published on: January 7, 2019
Lipopeptide with a RGDK tetrapeptide sequence can selectively target genes to proangiogenic alpha5beta1 integrin
Dipankar Pramanik1, Bharat K Majeti, Goutam Mondal
1Division of Lipid Science and Technology, Pharmacology Division, Indian Institute of Chemical Technology, Hyderabad 500607, India.
Abstract:
Integrins, the major class of alphabeta heterodimeric transmembrane glycoprotein receptors, play crucial roles in mediating tumor angiogenesis. Genetic ablation experiments combined with use of antibodies/peptide ligands for blocking either alpha(5) or beta(1) integrins have convincingly demonstrated alpha(5)beta(1) integrin to be unquestionably proangiogenic among the 24 known integrin receptors. Herein, we report on a novel RGDK-lipopeptide 1 that targets selectively alpha(5)beta(1) integrin and is capable of targeting genes to mouse tumor vasculatures.
Insights
A novel RGDK-lipopeptide targets alpha(5)beta(1) integrin, a key receptor in tumor blood vessel formation. This peptide can deliver genes to mouse tumor vasculature, offering a new therapeutic approach.
Area of Science:
- Molecular biology
- Oncology
- Biochemistry
Background:
- Integrins are transmembrane receptors crucial for cell adhesion and signaling.
- Tumor angiogenesis, the formation of new blood vessels in tumors, is essential for tumor growth and metastasis.
- Alpha(5)beta(1) integrin is a well-established proangiogenic receptor involved in tumor vascularization.
Purpose of the Study:
- To investigate a novel RGDK-lipopeptide as a selective targeting agent for alpha(5)beta(1) integrin.
- To evaluate the potential of this lipopeptide for gene delivery to tumor vasculature.
Main Methods:
- Utilized genetic ablation and blocking antibodies/peptide ligands to confirm the role of alpha(5)beta(1) integrin in angiogenesis.
- Developed and characterized a novel RGDK-lipopeptide.
Main Results:
- Confirmed alpha(5)beta(1) integrin as a proangiogenic factor among known integrin receptors.
- Demonstrated that the novel RGDK-lipopeptide selectively targets alpha(5)beta(1) integrin.
- Showcased the lipopeptide's capability for gene targeting to mouse tumor vasculatures.
Conclusions:
- The RGDK-lipopeptide is a promising selective targeting agent for alpha(5)beta(1) integrin.
- This lipopeptide holds potential for targeted gene therapy in cancer by delivering genes to tumor blood vessels.
